Brief: Allarity Therapeutics Granted FDA Fast Track Designation For Stenoparib For The Treatment Of Advanced Ovarian Cancer
26/08/2025 13:22
Aug 26 (Reuters) - Allarity Therapeutics Inc ALLR.O: ALLARITY THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION FOR STENOPARIB FOR THE TREATMENT OF ADVANCED OVARIAN CANCER Source text: ID:nGNXc3pTZ0 Further company coverage: ALLR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic